5323312026-04-012026-06-305323312026-04-012026-06-30in-capmkt:OtherExpenses1Member5323312026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532331AJANTPHARMNAINE031B01049AJANTA PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-07-302026-07-20INRCroresQuarterlyFirst quarterSingle segmentPharmaceutical2026-07-3013:30:002026-07-3014:28:00Not applicable2026-04-012026-06-30UnauditedConsolidated16259600000709000000169686000002965100000669200000-35580000038111000003180000044500000049342000001250060000044680000000446800000010272000009860000011258000000334220000000003342200000-4260000032996000003299600000032996000000250700000226.7526.720026.7526.72Notes : <br /> 1. The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2026. The statutory auditors have expressed an unmodified conclusion. The review report has been filed with the stock exchange and is available on company website. The consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> <br /> 2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. <br /> <br /> 3. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2025. <br /> <br /> 4. Board of Directors have approved 1st interim dividend of Rs. 399.79 Crore for financial year 2026-27 to its shareholders@ Rs. 32 per share on the face value of Rs. 2 per share. <br /> <br /> 5. Other income / Other expense includes : 3 months ended Year Ended <br /> <br /> Rs. in Crore 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 <br /> <br /> Foreign exchange gain (in other income) 50.47 44.37 9.38 97.17 <br /> Foreign exchange loss (in other expense) 30.59 41.70 25.15 103.04 <br /> <br /> 6. In August 2025, the Income Tax Authorities carried out search operations and the Company filed the return for the block period from 1 April 2019 to 17 November 2025 on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the consolidated financial results for the quarter ended 30 June 2026, if any, is currently not ascertainable. <br /> <br /> 7. The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals". <br /> <br /> 8. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.Other expenses4934200000Items that will not be reclassified subsequently to profit or loss-51100000-51100000-17900000Items that will be reclassified subsequently to profit or loss-9400000-94000000-42600000